Avantor Completes Acquisition of Masterflex
Following the acquisition, Avantor will have access to Masterflex’s various bioproduction operations.
Avantor announced on Nov. 1, 2021, that it had completed a previously announced acquisition of the Masterflex bioprocessing business and its related assets from Antylia Scientific, a portfolio company. Masterflex is an Illinois-based manufacturer of peristaltic pumps and aseptic single-use fluid transfer technologies.
According to a company press release, the Masterflex acquisition is intended to strengthen Avantor's offering in bioproduction platforms such as monoclonal antibodies, cell and gene therapy, and messenger-ribonucleic acid. Masterflex also supports both therapy and vaccine manufacturing, including those related to COVID-19.
"The acquisition of Masterflex extends Avantor's single-use offering and gives us a complete end-to-end solution for aseptic fluid transfer throughout the bioproduction workflow," said Michael Stubblefield, president and CEO of Avantor, in a company press release. "The acquisition demonstrates our commitment to the growing biopharma market and to providing more comprehensive solutions to some of the world's most complex challenges in therapy and vaccine development."
Source: Avantor
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
